Clinical evaluation of a real-time optoelectronic device in cervical cancer screening
Eur J Obstet Gynecol Reprod Biol. 2021 Sep 28:S0301-2115(21)00482-6. doi: 10.1016/j.ejogrb.2021.09.027. Online ahead of print.ABSTRACTOBJECTIVE: Early screening and intervention are crucial for the prevention and treatment of cervical cancer. TruScreen is a real-time, intelligent, pathological diagnostic technology designed for cervical cancer screening. The aim of this study was to evaluate the clinical value of TruScreen in screening for cervical lesions.STUDY DESIGN: A total of 458 women aged between 25 and 65 years were recruited to receive cervical cancer screening, including human papillomavirus (HPV) testing, cytological testing using the ThinPrep cytology test (TCT), and TruScreen from December 2018 to January 2020. The clinical performance of TruScreen, alone and in combination with HPV testing, was evaluated to detect cervical intraepithelial neoplasia grade 2 or worse (CIN2+ or CIN3+).RESULTS: For detection of CIN2+, the sensitivity and specificity of TruScreen were 83.78% and 78.86%, respectively. The specificity of TruScreen was significantly higher than those of HPV testing (50.59%, P
Indian J Med Res. 2021 Dec 2. doi: 10.4103/ijmr.IJMR_857_20. Online ahead of print.ABSTRACTCervical cancer is the fourth most common cancer in women in the world. To eliminate cervical cancer by 2030, the World Health Organization has given the target of 70 per cent coverage of twice lifetime screening. A multitude of screening methods are available, including cytology, human papillomavirus (HPV) DNA testing and visual inspection tests. Precision tests, including molecular and protein biomarkers such as DNA methylation, p16 immunostaining, and HPV mRNA testing help to enhance specificity of the screening. Worldwide HPV DNA...
This study compared VIA sensitivity and specificity in rural indigenous Guatemalan communities, to that of oncogenic human papillomavirus (HPV) testing for detection of precancerous changes, using cytology as the reference standard. Between 3–8 September 2017, trained nurses examined 222 women aged 23–58 years with VIA. Specimens for liquid-based cytology and HPV testing were obtained prior to VIA with a cytobrush and transported in PreservCyt to a US clinical laboratory. VIA and HPV test sensitivities were assessed as proportions of women with abnormal cytology that had abnormal VIA or HPV results, res...
The Human papillomavirus (HPV) is a tiny double-stranded DNA virus (1). There are over 100 different forms of HPV, with 40 of them affecting the genital tract (2). Based on their epidemiological relationship with cervical cancer, sexually transmitted HPV is divided into two categories: low-risk (LR) and high-risk (HR) (3). The HR HPV encodes viral oncogenes known as E6 and E7, which are necessary to initiate and maintain epithelial cell neoplasia (4). Chronic infection with HR HPV is the main cause of cervical cancer, the fourth leading cause of cancer death in women worldwide (5).
Conclusion: The diagnosis of AGC may be related to the preneoplastic/neoplastic processes. A further comprehensive histopathological examination is required in women with AGC, aged 50 years and older, postmenopausal, HPV-positivity and concomitant squamous cell abnormality Clinicians should consider ovarian pathologies when there is no pathological finding on endometrial or cervical histopathological examination.
CONCLUSION: Our findings indicate that HPV test with some PCR-based assay on urine versus clinician-collected samples demonstrate similar clinical accuracy to detect CIN2 or worse. It suggests that urinary HPV test may present itself as a decent alternative screening tool for the detection of cervical pre-cancer.TRIAL REGISTRATION: PROSPERO identifier: CRD42021227901.PMID:34783207 | DOI:10.3802/jgo.2022.33.e4